1-631-338-8059 info@cd-genomics.com

Custom Type 1 Diabetes Panel

What is type 1 diabetes?

Type 1 diabetes (T1D), also known as juvenile diabetes, accounts for 5-10% of all cases of diabetes. T1D is characterized by the failing to produce insulin. It is estimated that 80,000 children are suffering from T1D each year. The pathogenesis of type 1 diabetes involves in a combination of genetic and environmental factors, and the specific mechanisms have not yet been elucidated. Studies have shown that the pathogenesis of T1D may be related to the mutation of HLA gene or viral infection, which leads to the destruction of β-cells in patients. The classic symptoms are frequent urination, increased thirst, increased hunger and weight loss. Other symptoms may include blurred vision, fatigue and poor wound healing.

Disease-related gene description

The occurrence of type 1 diabetes involves in more than 50 genes. Depending on the combination of loci, they can be dominant, recessive or somewhere in between. IDDM1, which is located in the major histocompatibility complex (MHC) class II region of chromosome 6, and the staining region is 6p21 which is associated with type 1 diabetes. Certain variants of this gene increase the risk of reduced histocompatibility in type 1 diabetes. Studies have also shown that mutations in the IL2RA gene associated with regulatory T cells reduce the ability to inhibit the proliferation of autologous effector T cells. This increases the risk of developing type 1 diabetes in the body. Researchers have also screened genes associated with type 1 diabetes, including CTLA4, PTPN22, CGRP, AFF3, etc.

To better understand the relationship between mutations in certain related genes and the development of type 1 diabetes, we offer a comprehensive library of type I diabetes-related genes. Targeted DNA sequencing technology utilizing the Illumina MiSeq or Ion PGM system is provided. You can select the gene of interest from the library for testing.

Custom type 1 diabetes panel offers but not limited to:

Targeted amplicon sequencing by Illumina MiSeq/Ion PGM system is utilized to obtain the most accurate results, so that we could detect low-frequency type 1 diabetes variants.
Only sequencing the customizable type 1 diabetes panel suits your requirements, increases throughput and saves costs.
Strict quality control throughout the pipeline workflow ensures the validity and repeatability of the sequencing.
In order to obtain accurate results, each detected change in gene level will be further verified.
Custom panel content is based on the latest research frontiers on type 1 diabetes, covering all possible genes.
You can choose the panel content of interest from our type 1 diabetes library, or discuss your custom type 1 diabetes panel requirements, then we can provide you with a personalized panel.

Choose the genes that suit you from the type 1 diabetes gene list

ABCC8	AFF3	CGRP	CTLA4
ERBB3	ERBB4	HLA-DRB1	HLA-DQB1
HMGB	IDDM1	IL2RA	IL-6
IKZF1	KCNJ11	NGF	Nrf2
PDX-1	PTPN22	PHTF1	RIG-I
TCF7L2	TLR2	TLR4

Specimen requirements of our custom type 1 diabetes panel

Specimen: serum or extracted DNA (no FFPE).
Volume: 2 mL serum, 3 μg DNA.
Collection: serum is separated and stored in cold storage. Serum samples are placed at room temperature and samples with hemolysis, lipemia or severe jaundice are not accepted. DNA samples are stored in TE buffer or equivalent.
Container: serum separator tube, lavender-top (EDTA) tube.

Gene panel workflow

For more information about the Custom Type 1 Diabetes Panel or need other amplification requirements, please contact us.

References:

Daneman D. Type 1 diabetes[J]. The Lancet, 2006, 367(9513): 847-858.
Davies J L, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature, 1994, 371(6493): 130.
Rubio-Cabezas O, et al. Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options. Hormone research in paediatrics, 2013, 80(3): 137-146.
Bluestone J A, et al. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature, 2010, 464(7293): 1293.
Boj S F, et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell, 2012, 151(7): 1595-1607.

* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.

Online Inquiry

SUITE 111, 17 Ramsey Road, Shirley, NY 11967, USA
1-631-338-8059
1-631-614-7828
info@cd-genomics.com

Top

Inquiry Basket

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies